| First Author | Krishnamurthy K | Year | 2020 |
| Journal | Brain Res | Volume | 1733 |
| Pages | 146685 | PubMed ID | 32007397 |
| Mgi Jnum | J:293293 | Mgi Id | MGI:6445858 |
| Doi | 10.1016/j.brainres.2020.146685 | Citation | Krishnamurthy K, et al. (2020) ApoE mimetic improves pathology and memory in a model of Alzheimer's disease. Brain Res 1733:146685 |
| abstractText | Alzheimer's disease (AD) is the most common form of dementia and is characterized pathologically by Abeta plaques. Current treatments are purely symptomatic despite decades of intensive research interest. Notably, patients with the APOE4 allele are at increased risk for developing AD. One hypothesis regarding the mechanism by which the APOE4 allele might increase AD risk is loss of adaptive function, raising the possibility that the exogenous administration of apoE mimetics would have therapeutic effects. In this study, we utilized a previously characterized murine model of AD containing human APP, PS1 and APOE4TR, the APP/PS1/APOETR mouse. We treated male APP/PS1/APOETR mice with the apoE mimetic CN-105 or vehicle for 40d, beginning either at 14-18 or 25-28 weeks of age. After termination of treatment we tested animals in both Morris water maze and contextual fear conditioning, and examined soluble Abeta by biochemistery and Abeta deposition in cortex by unbiased stereology. We found that transient treatment with CN-105 for 40d beginning at 14-18 weeks reduced Abeta pathology and rescued memory deficits in male APP/PS1/APOETR mice. Notably, delaying treatment onset to 25-28 weeks did not produce as robust an effect. These results suggest CN-105 treatment in a mouse model of AD results in a reduction in AD pathology and improved behavioral outcomes when administered early in the course of disease. As CN-105 has an excellent safety profile and is already in clinical trials, these findings raise the possibility that CN-105 represents a novel and translatable therapeutic strategy for AD. |
